FDA
-
-
-
-
-
-
-
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
-
-
-
-
-
-
-
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
-
-
-
-
-
-
-
Fennec Pharmaceuticals plans private offering of common shares
-
-
-
-
-
-
-
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
-
-
-
-
-
-
-
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
-
-
-
-
-
-
-
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
-
324,765 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

